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Abstract
The occurrence of resistant viruses to any of the anti-HIV-1 compounds used in the current therapies against AIDS underlies
the urge for the development of new drug targets and/or new drugs acting through novel mechanisms. While all anti-HIV-1
nucleoside analogues in clinical use and in clinical trials rely on ribose modifications for activity, we designed nucleosides
with a natural deoxyribose moiety and modifications of position 8 of the adenine base. Such modifications might induce a
steric clash with helix aH in the thumb domain of the p66 subunit of HIV-1 RT at a distance from the catalytic site, causing
delayed chain termination. Eleven new 29-deoxyadenosine analogues modified on position 8 of the purine base were
synthesized and tested in vitro and in cell-based assays. In this paper we demonstrate for the first time that chemical
modifications on position 8 of 29-deoxyadenosine induce delayed chain termination in vitro, and also inhibit DNA synthesis
when incorporated in a DNA template strand. Furthermore, one of them had moderate anti-HIV-1 activity in cell-culture. Our
results constitute a proof of concept indicating that modification on the base moiety of nucleosides can induce delayed
polymerization arrest and inhibit HIV-1 replication.
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Introduction
Reverse transcription of the single-stranded genomic RNA into
double-stranded DNA that will be integrated into the host genome
is a key step of HIV-1 replication. This process is performed by the
virally encoded reverse transcriptase (RT), which possesses RNA-
and DNA-dependant DNA polymerase activity as well as RNase
H activity [1].
After three decades of research, Highly Active Anti-Retroviral
Therapy (HAART) [2,3] is the best option to treat HIV-1-infected
individuals. This therapeutic strategy combines three to five
compounds mostly targeting RT and the viral protease. HAART
quickly and strongly reduces the viral load, but it does not
eradicate HIV-1 and drug-therapy is life-long [4]. Despite the
existence of new drugs targeting viral entry (enfuvirtide [5] and
maraviroc [6]) and integration (raltegravir [7]), that are generally
used in later stages during treatment or for patients who failed the
standard therapies, RT remains a major target of antiviral agents,
with presently 12 clinically approved drugs. These drugs are
divided into the two broad classes of nucleoside (and nucleotide)
reverse transcriptase inhibitors (NRTIs) and non-nucleoside
reverse transcriptase inhibitors (NNRTIs). NNRTIs are allosteric
non-competitive RT inhibitors [8,9] whereas all the approved
NRTIs are competitive analogues of the natural dNTP substrates
of RT. Once incorporated into the elongating DNA chain, they
act as chain terminators, due to the lack of a 39-OH group (for
reviews, see [10,11,12]).
HIV-1 actively replicates in untreated infected individuals, and
RT, which lacks proof-reading activity, is a highly error prone
enzyme [13,14]. As a consequence, suboptimal therapies lead to
the emergence of resistant viruses, and a significant proportion of
individuals are primo-infected with drug-resistant HIV-1 strains. In
the case of NRTIs, resistance mechanisms fall into two classes (for
reviews, see [10,12,15,16]): (1) decreased incorporation efficiency of the
triphosphorylated form of the nucleoside analogue, by enhanced discrim-
ination of the NRTI with comparison to the natural dNTPs, either
due to decreased binding of the NRTI and/or to a diminished rate
of incorporation; (2) removal of the NRTI from the end of the newly
synthesized DNA by RT, due to phosphorolysis, the reverse reaction
of polymerization. Excision of 39-azido-39-deoxythymidine (AZT),
and to a lesser extend 29,39-didehydro-29,39-dideoxythymidine
(d4T), from the 39 end of an elongating DNA primer is facilitated
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by a set of up to six mutations in the pol gene, including M41L,
D67N, K70R, L210W, T215F/Y and K219E/Q, collectively
referred to as Thymidine-analogue resistant mutations (TAMs). It
has been shown that AZT-resistant RT is not only able to use PPi,
but also a nucleotide triphosphate as PPi donor, most likely ATP in
vivo, to excise the chain terminator (for a review, see [17]).
The inevitable occurrence of resistance to NRTIs, and indeed to
all anti-HIV-1 drugs, underlies the need for new drugs directed
against different targets and/or acting against existing targets via
alternative mechanisms of action. In the case of HIV-1 RT,
several NNRTIs are in late stage clinical trials and the RNase H
activity of the enzyme is also considered to be an attractive target
for the development of antiretrovirals (for recent reviews, see
[10,11,12]).
One important consideration for the development of new
inhibitors is their efficacy against existing drug-resistant RTs.
Nucleoside analogues that (1) are incorporated into DNA by RT,
(2) do not block DNA synthesis at their point of incorporation, and
(3) block DNA synthesis only when a few natural dNTPs have
been added after them should, to a large extent, be efficient against
resistant RT acting through the excision mechanism. Such
compounds have been developed recently and are called
‘‘delayed chain terminators’’ or DCTs. The first compound to
display delayed polymerization arrest activity in vitro was a fixed
conformation 29-deoxyadenosine analogue, where the pseudosu-
gar ring is locked in the North conformation [18,19]. The
triphosphorylated form of this nucleoside analogue is efficiently
used as a substrate by HIV-1 RT in vitro and induces partial
polymerization arrest when 2 or 3 more nucleotides are incor-
porated thereafter. It is also relatively resistant to excision by wild-
type (WT) and resistant RTs. However this compound is not a
drug candidate since it is poorly phosphorylated in cultured cells.
Besides, several groups have investigated the properties of NRTIs
bearing 49 modifications on the pseudosugar ring. First [20] and
second generation 49-ethynyl-substituted compounds [21] dis-
played promising antiviral activities [22] and low cytotoxic effects
[23]. Recently, it was shown that 49-ethynyl-2-fluoro-29-deoxya-
denosine triphosphate inhibits RT translocation [24]. 49-Methyl
and 49-ethyl-thymidine and adenosine also inhibit HIV-1 RT in
vitro and in vivo, but in a temporal rather than a spatial sense and
are therefore not strict delayed chain terminators [25,26]. Finally,
the guanosine analogue entecavir (ETV), a potent antiviral used to
treat hepatitis B virus infected patients, which retains its 39-OH
group, has recently been shown to inhibit HIV-1 RT [27].
Interestingly, chain termination three nucleotides after the ETV
incorporation site is the major mechanism of inhibition, in vitro
[27], most likely because the 39-end of the primer is being
‘‘repelled’’ from the active site. In addition, the presence of ETV at
a distance from the catalytic site protects the elongating primer
from excision by TAM-containing RTs, making it the first
inhibitor acting by delayed chain termination that is active against
HIV-1 in cell culture and in the clinic [27,28].
The NRTIs used in the clinic and all DCTs developed so far are
modified on their sugar moiety, keeping open the possibility of
HIV-1 RT might develop cross-resistance to classical NRTIs and
DCTs: for instance both 29,39-dideoxy-39-thiacytidine (3TC) and
ETV select the M184V resistance mutation in HIV-1 RT [29].
Here we tested the possibility of developing DCTs with a natural
deoxyribose moiety and a modified base. We reasoned that such
compounds might induce delayed chain termination because of a
steric clash with helix aH in the thumb domain of the p66 subunit
of HIV-1 RT and early mutational analysis of helix aH has indeed
proven its importance for polymerization [30]. Several groups
have investigated the synthesis of 8-substituted-29-dA derivatives
[31,32,33] but few antiviral data have been reported so far for
these compounds. We designed, synthesized, and tested eleven of
these analogues of 29-deoxyadenosine. Most of them induce
delayed chain termination in vitro, and one has a moderate anti
HIV-1 activity in cell culture. Our results constitute a proof of
concept indicating that modification on the base moiety of
nucleosides can induce delayed polymerization arrest and inhibit
HIV-1 replication.
Results
The goal of our work was to develop new NRTIs acting as
delayed chain terminators (DCTs). To that aim, we sought to
introduce modifications on the natural deoxynucleosides that could
interfere with the interaction between the primer/template (P/T)
complex and helix aH located in the thumb domain of HIV-1 RT
(Figure 1A). Indeed, this interaction, 3 to 6 nucleotides downstream
of the RT active site is crucial for DNA synthesis [30]. The crystal
structure of a P/TNRTNincoming dNTP complex indicates that
modifications at position 5 of pyrimidines or position 8 of purines
should not prevent incorporation of DCTs into the nascent primer
chain, as this face of the incoming nucleotides makes no contact
with the RT active site [34] (Figure 1B). Hence, we decided to
synthesize and test a series of 29-deoxyadenosine analogues
substituted at position 8 with groups with different organic functions
and sizes (Figure 1C). Our DCTs are completely different from
traditional NRTIs as they possess an unmodified deoxyribose
moiety with a 39 hydroxyl group. We hypothesize that after
incorporation, the modifications will distort the DNA structure and
prevent proper interaction with the thumb domain of RT. To test
delayed polymerization arrest, we synthesized the phosphoramidite
derivatives of the different nucleoside analogues (Figure 1D) and
introduced them in DNA oligonucleotides that we used as primers
or templates in in vitro reverse transcription assays. Finally, we tested
the antiviral activity of the nucleoside analogues in cell culture.
Chemical synthesis
The synthesis of the 8-substituted-29-dA analogues 2a–g, 3 and
7 was achieved starting from 8-bromo-29-deoxyadenosine 1
(Figure 2). The nucleophilic displacement of the bromine atom
with several primary and secondary amines was performed on
the unprotected nucleoside 1 according to the strategy previously
described by the group of L.B. Townsend [32]. While preparation
of the 8-disubstituted-amino-dA derivatives 2a–e was performed
in methanol at room temperature, the 8-monosubstituted-amino-
29-dA nucleosides 2f–g required more vigorous conditions, and
the reactions were performed at 65uC. The 8-substituted-amino
nucleosides 2 a–g were obtained in moderate to good yields (60 to
97%). The 8-MeS-29-dA analogue 3 was obtained in 86% yield
by treatment of compound 1 with an aqueous solution of sodium
methanethiolate in dimethylformamide (DMF). 8-Carbamoyl-
29-dA derivative 7 was obtained starting from the previously
synthesized 8-methylthio-29-dA analogue 3. Acetylation of the two
hydroxyl groups of 3 was performed in quantitative yields using
acetic anhydride in pyridine while oxidation of the methylthio
group into sulfone was performed with potassium permanganate
in acidic conditions. Compound 5 was reacted with sodium
cyanate in DMF and gave compound 6 in 80% yield. Removal of
the acetyl groups and concomitant hydratation of the cyano
function by sodium hydroxide led to compound 7 in 56% yield.
2D-Noesy NMR experiments (Figure S1) showed correlations
between modifications introduced on carbon 8 and the H-29 (up)
and H-39 indicating that our nucleosides exist in the natural anti-
conformation.
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Next we synthesized the corresponding phosphoramidites
required for incorporation of 8-substituted-29-deoxyadenosines
into oligonucleotides (ODNs) for in vitro evaluation on RT.
Protection of the exocyclic amino group of compounds 2 a–g, 3
and 7 was achieved with N,N’-dimethylformamide-dimethylacetal
in methanol (Figure 3). The corresponding base protected
nucleosides 10 a–g, 11 and 12 were obtained in 75 to 90%
yields. The primary hydroxyl group of these compounds was
protected with a dimethoxytrityl group and compounds 13 a–g,
14 and 15 were obtained in good yields varying from 67 to 75%.
8-Vinyl-29-dA protected nucleoside 17 was prepared from
compound 16 according to the protocol previously described by
Ben Gaied et al. [35]. The synthesis of the 8-ethyl-29-dA analogue
19 required for the phosphoramidite synthesis was realized
straightforward in two steps starting from the known protected
8-vinyl-29-dA, 16 [35] (Figure 3). Hydrogenation of protected 8-
vinyl-29-dA over palladium catalyst afforded the reduced ethyl
intermediate 18 in 94% yield. The amino group of 18 was
protected quantitatively with N,N’-dimethylformamide dimethyla-
cetal in methanol. The 39-hydroxyl group of the conveniently
protected nucleoside analogues 13 a–g, 14, 15, 17 and 19 was
esterified by chloro-cyanoethyl-N,N’-diisopropyl-phosphoramidite
in dicloromethane in presence of diisopropyl-ethylamine to obtain
the corresponding phosphoramidite building block 20a–g, 21,
22, 23 and 24 in yields varying from 70 to 90%.
The building blocks 20 a–g, 21, 22, 23 and 24 were used to
synthesize the ODN sequences depicted in Figures 4A and 5A.
The 18 mer ODNs were prepared on a Universal Support
allowing the introduction of the modification at the 39 end. The
cleavage from this support required to be done by ammonia in
methanol in dry conditions. Whereas ODNs containing the
modifications 2b, 2f–g, 3, 8 and 9 were obtained in satisfying
yields, the ones modified with 2a and c were only obtained as
traces and we were not able to produce and/or purify ODNs
containing modifications 2d–e and 7. For this reason in vitro
experiments were only performed with 6 modified nucleoside
analogues.
29-dA analogues induce delayed chain termination
The ability of DCTs to induce chain termination was first
estimated by following the in vitro synthesis of a 178 nucleotide long
(2) strong-stop DNA, the reverse transcription product obtained
when a primer is hybridized to the Primer Binding Site (PBS)
sequence of the 1–311 HIV-1 MAL RNA. These experiments
were performed with a standard 10 nM concentration of HIV-1
RT. The primers we used were 19-mer ODNs, complementary to
the PBS extended by one nucleotide at its 59 end. The primers
were either unmodified or modified with a DCT incorporated at
the penultimate position of the 19-mers (Figure 4A). In the absence
of any modification on the primer, DNA synthesis was processive,
Figure 1. Rationale and nucleos(t)ide analogues used in this study. A. Stereoview of the interaction between helices aH and aI of RT thumb
domain according to the X-ray structure of HIV-1 RT in complex with a primerNtemplate complex and an incoming dNTP (37). The side chains of
helices aH and aI interacting with the minor groove of the primerNtemplate complex are in yellow and orange, respectively; the primer is in blue, the
template in green, and the incoming dNTP in red. B. Close up of the dNTP binding site. The surface of the p66 subunit of HIV-1 RT is in grey, the
template is in green, the primer in blue, and the incoming dTTP is in red, except positions 5 and 6 of the pyrimidine ring which are in yellow. Positions
7 and 8 of an incoming dATP would occupy the same position in the structure. C. Nucleoside analogues and D. Phosphoramidites used in this study.
DMTr is used for dimethoxytrityl group.
doi:10.1371/journal.pone.0027456.g001
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Figure 2. Synthesis of 8-modified nucleoside analogues 2a–g, 3 and 7. (i) Primary amine, MeOH, 65uC, 24 h or secondary amine, MeOH,
room temperature, 24 h; (ii) MeSNa 25%/H2O, DMF, room temperature, 3 h; (iii) Ac2O, pyridine, room temperature, 5 h; (iv) KMnO4, CH3CO2H/H2O
(50/50 v/v), 0uC, 1 h; (v) NaCN, DMF, room temperature, 3 h; (vi) NaOH 1 M, H2O, room temperature, 7 h.
doi:10.1371/journal.pone.0027456.g002
Figure 3. Synthesis of phosphoramidite building blocks 20 a–g, 21, 22, 23 and 24. (i) Me2NCH(OMe)2, MeOH, room temperature, 17 h; (ii)
DMTrCl, pyridine, room temperature, 17 h; (iii) Me2NCH(OMe)2, DMF, room temperature, 4 h; (iv) H2, Pd/C (10%), EtOAc, CH2Cl2, room temperature,
4 h; (v) (iPr)2N(CE)PCl, (iPr)2NEt, CH2Cl2, room temperature, 2.5 h.
doi:10.1371/journal.pone.0027456.g003
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with little pausing in the first 36 nucleotides of the (2) strand
DNA product and the vast majority of the primer was
extended after 5 minutes (Figure 4B). Amongst all the DCTs
that were incorporated into DNA primers, only 8-iBu-N-dA
(2g) gave the same pattern as the unmodified primer
(Figure 4B), suggesting that this modified nucleotide behaves
like a natural dNTP and does not induce delayed polymeri-
sation arrest. Extension reactions performed with 19-mer DNA
primers containing the DCT at the penultimate position from
its 39 end showed that all the other nucleotide analogues tested
(2b, 2f, 3, 8 and 9) strongly inhibit (2) strong-stop DNA
synthesis with, in most cases, a strong pausing site at position
+3 (Figure 4B). Quantification of these gels showed that when
HIV-1 RT was used at a concentration of 10 nM, incorpora-
tion of 8-iPr-N-dA (2f) or 8-Et-dA analogue (9) in the primer
strand inhibited (2) strong-stop DNA synthesis by 48 and
45%, respectively, while the other DCTs were more potent,
causing an ,90% inhibition (Table 1).
In order to quantify the inhibitory effects more accurately, we
performed +6 DNA synthesis on the same RNA template as
above, in the presence of 10 or 30 nM of HIV-1 RT. These
experiments were done in the presence of only three of the natural
dNTPs (dCTP, dGTP and dGTP), the fourth one being a dideoxy-
nucleotide, ddATP. ddATP base-pairs with an uracile that is
present in the template, six nucleotides downstream from the
position at which the DCT was placed in the elongated primer
(Figure 4A). When DCTs were incorporated at the penultimate
position of an 19-mer DNA primer, 8-Et,Me-N-dA (2b), 8-iPr-N-
dA (2f) and 8-MeS-dA (3) clearly induced a delayed chain
termination at both 10 and 30 nM of HIV-1 RT, as evidenced by
the accumulation of n+3 products (Figure 4C and 4D), n referring
to the position of the DCT (Figure 4A). As expected from the
results presented above, 8-iBu-N-dA (2g) did not impact (2) strand
DNA synthesis. Quantification of the ‘‘n+3’’ and ‘‘n+6’’ products
in the absence and presence of modifications allowed us to
calculate a percentage of inhibition (see legend to Table 1). When
HIV-1 RT was used at a 10 nM concentration, the inhibition
varied between 15 to 80% depending on the nature of the DCT.
Increasing the RT concentration to 30 nM did not abolish the
effect of the active compounds 2b, 2f and 3, but reduced the
overall effect of all 4 compounds on (2) strand DNA synthesis, as
indicated by the percentage of inhibition which varied from 0 to
67% (Table 1). The same results were obtained when 8-iPr-N-dA
(2f), 8-iBu-N-dA (2g) and 8-MeS-dA (3) were located at the last
position of an 18-mer DNA primer: at a 10 nM RT concentration,
8-iBu-N-dA (2g) had no effect on (2) strand DNA synthesis
whereas 8-iPr-N-dA (2f) and 8-MeS-dA (3) inhibited it by 81 and
77%, respectively. However, with modifications located at the 39
end of the primer, the increase in RT concentration to 30 nM was
less harmful to DNA synthesis than when DCT was placed at the
penultimate position. Noticeably 8-Et,Me-N-dA (2b) located at the
last position of a DNA primer acted as an immediate chain
terminator whatever the RT concentration was (Figure 4E and 4F
and Table 1). Interestingly, we also found that when DNA rather
than RNA was used as a template, 8-MeS-dA (3) did not act as a
delayed chain terminator (data available in Figure S2). This
finding most likely extends to all 29-dA analogues described in this
paper and correlates with the finding that 49-C-ethyl-29-dA also
Figure 4. Effect of DCTs on (-) strand DNA synthesis. A. Template and primers used for (-) strand DNA synthesis. The template used is 1-311
HIV-1 MAL RNA, for which only part of the sequence is shown. The boxed nucleotides correspond to the Primer Binding Site (PBS). 18- and 19-mer
DNA primers were used. X corresponds to either dAMP or a 29-dA analogue, inserted at the 39 end (18-mer) or at the penultimate (19-mer) position of
the primer. ‘‘n’’ corresponds to the 39 end of the 18-mer primer strictly complementary to the PBS. B. Time course of in vitro (-) strand strong-stop
DNA synthesis using 19-mer DNA primers containing or not a DCT at the penultimate position. Ten nM of primer/1–311 HIV-1 RNA complexes were
pre-incubated with 10 nM of RT and polymerization was initiated by the addition of 50 mM of each of the four dNTPs. Reactions were stopped after
15 and 30 sec, 1, 5, 10, 20 and 30 min. C./D. Time course of in vitro (2) strand ‘‘n+6’’ DNA synthesis using 19-mer DNA primers containing or not a
DCT at the penultimate position. Reaction set-up was the same as previously except that dNTPs were replaced by 20 mM of dTTP, dGTP and dCTP as
well as 50 mM of ddATP. In C., 10 nM of RT were used whereas in D. 30 nM of RT were used. Reactions were stopped after 30 sec, 1, 5, 10, 20 and
30 min. ‘‘+6’’ refers to the 6th nucleotide to be added with respect to the 59 end of the PBS sequence. E./F. Time course of in vitro (2) strand ‘‘n+6’’
DNA synthesis using 18-mer DNA primers containing or not a DCT at the ultimate position. Reaction set-up was the same as previously described for
C./D. In E., 10 nM of RT were used whereas 30 nM of RT were used in F.
doi:10.1371/journal.pone.0027456.g004
Table 1. Quantitative analysis of (2) and (+) strand DNA synthesis inhibition.
Inhibition of (2) strand DNA synthesis (DCT in the primer)
Inhibition of (+) strand DNA
synthesis (DCT in the template)
DCT at 39-end-18 mer- DCT at penultimate position-19 mer-
10 nM RT 30 nM RT 10 nM RT 30 nM RT 10 nM RT 30 nM RT
8-Et,Me-N-dA 2b termination termination 93%* 64% 48% 60% 65%
8-iPr-N-dA 2f 81% 90% 48%* 80% 60% 50% 38%
8-iBu-N-dA 2g 12% 8% nd 15% 0% 2% 1%
8-MeS-dA 3 77% 64% 88%* 68% 67% 46% 47%
8-vinyl-dA 8 nd nd 90%* nd nd 37% nd
8-Et-dA 9 nd nd 45%* nd nd 34% nd
To estimate inhibition of (2) strand DNA synthesis, DCTs were introduced at the 39 end or the penultimate position of DNA primers. When inhibition of DNA synthesis
was evaluated using the ‘‘n+6’’ DNA synthesis assay, the percentage of inhibition was calculated as follow: 1- (% elongated product ‘‘+ DCT’’/% elongated product ‘‘-DCT’’).
The percentage of elongated product in the presence or absence of DCT was the ratio ‘‘n+6’’/(‘‘n+6’’ + ‘‘n+3’’). Alternatively, the percentage of inhibition was calculated
based on inhibition of full-length (2) strand DNA synthesis (*). To study the effect of DCTs on (+) strand DNA synthesis, the nucleoside analogues were incorporated into
31-mer DNA templates. The percentage of inhibition of DNA synthesis was calculated as indicated in the legend of figure 5.
*: percentage of inhibition obtained using the (2) strand strong-stop DNA synthesis assay; nd: not determined.
doi:10.1371/journal.pone.0027456.t001
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blocks DNA synthesis exclusively in the presence of an RNA
template, both in vitro and in vivo [26,36].
29-dA analogues inhibit (+) strand DNA synthesis
Since delayed polymerization arrest is not complete during (2)
strand strong-stop DNA synthesis (Figure 4 and Table 1), we
incorporated DCTs into a DNA template and tested their effect on
(+) strand DNA synthesis. To that aim, 31-mer DNA oligonucle-
otides containing or not the DCT analogues (2b, 2f, 2g, 3, 8
and 9) twelve nucleotides from their 59 end were chemically
synthesized (Figure 5A). In the presence of a suitable primer, the
DCT analogues face the second nucleotide to be incorporated by
RT (Figure 5A), thus allowing for several possible outcomes: (i) the
natural dNTP is incorporated opposite the DCT analogue and is
extended, leading to normal DNA synthesis; (ii) the presence of the
DCT analogue does not allow incorporation of the natural dNTP,
mainly generating a primer that is extended by one nucleotide; (iii)
the natural dNTP is incorporated but elongation is then blocked or
delayed, generating a strong pausing product that reflects the
accumulation of a primer extended by 2 nucleotides.
In the presence of an unmodified 31-mer DNA template,
extension of the primer is very fast and almost complete within
5vmin, with very little intermediate products (Figure 5B and 5C).
The presence of 8-iBu-N-dA (2g) in the template does not affect
this pattern (Figure 5B and 5C), suggesting that this analogue
behaves similarly to its natural counterpart. For all the other
nucleoside analogues (8-Et,Me-N-dA (2b), 8-iPr-N-dA (2f), 8-
MeS-dA (3), 8-vinyl-dA (8) and 8-Et-dA (9), enzyme pausing is
obvious at positions n+1 and mainly n+2, directly opposite to the
DCTs in the template strand, at RT concentrations of 10 or
30 nM (Figure 5B and 5C)). The blockage of DNA synthesis is
however not complete and full-length DNA synthesis products are
still visible. Overall, these results suggest that not only incorpo-
ration of a nucleotide opposite some DCT analogues, but also
extension of a duplex terminated by a base-pair involving a DCT
analogue are slowed down. The impact of the presence of DCT
analogues in the template strand was measured by comparing the
percentage of final product in the presence and absence of DCTs.
Quantitative data indicated that, for efficient compounds,
inhibition of (+) strand DNA synthesis ranges from 34 to 60% at
Figure 5. Effects of DCTs on (+) strand DNA synthesis. A. Templates and primer used to test the effect of delayed chain terminators on (+)
strand DNA synthesis. Synthetic 31-mer DNA oligonucleotides, containing or not the 29-dA analogues, were used as templates. X corresponds to
either dAMP or a 29-dA analogue. An 18-mer DNA oligonucleotide was used as a primer in this assay. B. Time course of in vitro (+) strand DNA
synthesis when DCTs are inserted in synthetic DNA oligonucleotides that serve as templates. Ten nM of primer/template were pre-incubated with
10 nM of RT and the polymerization reactions were initiated by the addition of 50 mM of each of the four dNTPs. Reactions were stopped after 30 sec,
1, 5, 10, 20, 30 and 60 min. C. Reaction set-up was the same as in B. except that 30 nM of RT was used. The percentage of inhibition of DNA synthesis,
indicated below each gel, was calculated by comparing the percentage of final product obtained when a DCT is present in the template compared to
the percentage of final product obtained with an unmodified template. See also Table 1.
doi:10.1371/journal.pone.0027456.g005
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an RT concentration of 10 nM. Increasing the RT concentration
to 30 nM did not drastically affect the percentage of inhibition of
DNA synthesis which ranged from 38 to 65% (Table 1). These
results are in accordance with the ones recently published by Vu
et al. [26] on 49-C-ethyl-29-dA activity.
One 8-modified-29-dA analogue reduces HIV-1
replication in cell culture
The in vitro experiments we performed indicated that once
incorporated into the primer or the template strand, most of our
compounds are able to cause delayed termination of reverse
transcription. We thus addressed the antiviral activity of our
nucleoside analogues in cell culture. All the synthesized nucleoside
analogues (2a–g, 3, 7, 8 and 9) were tested for their ability to
reduce HIV-1 LAI in CEM-SS cells. Viral replication was
monitored by measuring the RT activity in the cell culture
supernatants, while compound’s cytotoxicity on uninfected cells
was assessed using an MTT assay [37]. Results are presented in
Table 2. One compound (2f) displayed a moderate activity
(EC50 = 14 mM) associated to a slight cytotoxicity (CC50 = 81 mM).
Discussion
Deoxyadenosine and deoxycytosine nucleoside analogues
locked into North (N) or South (S) conformations have been
synthesized previously [18] and tested for their ability to inhibit
DNA synthesis at a distance from the polymerization site. Only the
N-conformation locked analogues competed with natural dNTPs
and were incorporated by HIV-1 RT. They were effective in
blocking polymerisation 2 to 3 nucleotides after their incorpora-
tion site. Unfortunately, these analogues were not efficiently
phosphorylated by cellular kinases and are thus not suitable for
further development of anti-HIV-1 drugs. More recently, ETV,
which is used to treat hepatitis B virus infections, was shown to be
incorporated by HIV-1 RT and to block DNA synthesis at
position n+3 (26). In our work, rather than modifying the sugar
moiety of the nucleoside, we have chosen to synthesize compounds
that are modified on the base. More precisely, eleven analogues of
29-deoxyadenosine modified on position 8 of the purine ring were
designed and chemically synthesized. 2D-Noesy NMR experi-
ments indicated that for 8-iPr-N-dA, 8-MeS-dA or iBu-N-dA the
natural anti-conformation is preserved allowing the formation of
base pairing and the possible incorporation of the analogues into
the nascent viral DNA by RT.
To test the effect of the 29-dA analogues on (2) strand DNA
synthesis, we prepared their phosphoramidite derivatives (Scheme
2) and they were introduced at the 39 end or the penultimate
position of DNA primers by automated solid phase DNA synthesis.
Only oligonucleotides modified with compounds 2b, 2f–g, 3, 8
and 9 were obtained with satisfying yields and were used for in vitro
experiments. Once those primers were annealed to an RNA
template, the P/T complexes were elongated by HIV-1 RT in the
presence of natural dNTPs. In such an in vitro reverse transcription
assay, all but one of the 29-dA analogues inhibited (2) strand DNA
synthesis, with effects ranging from 45% to 90% of inhibition
(Figure 4 and Table 1). This inhibition is mainly due to strong
pausing 2 to 3 nucleotides from the DCT incorporation site
(Figure 4). Pausing induced by DCTs does not induce a permanent
blockage of reverse transcription at this site, but extension of
the paused products is hardly detectable at low (10 nM) RT
concentration (Figure 4B). At higher RT concentration (30 nM),
extension of the paused products can be detected at the last points
of the time course. Remarkably, we found that the 8-iBu-N-dA
(2g) analogue does not inhibit DNA synthesis at all whereas 8-
Et,Me-N-dA (2b), which displays delayed polymerisation arrest
effects when positioned at the penultimate position of the primer,
acts as a direct chain terminator when located at the 39 end of the
primer. Importantly, the overall observed effects during (2) strand
DNA synthesis are the predicted ones: DNA synthesis is blocked
at a distance from the catalytically active site. Notably, the
modifications carried by the adenosine ring are located within the
major groove of the P/T duplex, since in most cases HIV-1 RT
cannot incorporate nucleoside analogues that are modified on the
minor groove interacting site, the latter positions making extensive
interactions with the HIV-1 RT catalytic site [34]. Since
crystallographic structures of RTNP/T complexes clearly show
that interactions of the P/T duplex with aH and aI helices of the
thumb domain of HIV-1 RT take place in the minor groove
(Figure 1A), the delayed polymerisation outcome that is observed
in our experiments must be due to indirect effect(s). Further
investigations about the impact of the modifications that we
introduced on 29-dA on the structure of a DNA/DNA duplex, by
X-ray crystallography for example, would be of great interest.
Inhibition of (2) strand DNA synthesis was not complete in our
in vitro assays with any of the nucleoside analogues tested. We
therefore set out to test their capacity to inhibit the second round
of DNA synthesis, corresponding to (+) strand DNA synthesis once
nucleoside analogues have been incorporated into the (2) strand
DNA. Inhibition of (+) strand DNA synthesis has already been
documented for ETV [27]. With the exception of 8-iBu-N-dA, all
nucleoside analogues tested inhibited (+) strand DNA synthesis,
with an effect ranging from 34 to 65% of inhibition compared to
the situation in the absence of nucleoside analogue (Figure 5 and
Table 1).
Hence, all but one of the nucleoside analogues that we
conceived to inhibit DNA synthesis by delayed polymerisation
arrest effectively act by this mechanism in vitro. They also share the
additional benefit of displaying a cumulative effect, since they
inhibit the synthesis of both (2) and (+) DNA strands.
One of our nucleoside analogues, 8-iPr-N-dA, has a moderate
anti-HIV-1 activity in a cell-based assay. The reason why the other
compounds are inactive in this assay is presently unknown. It is
Table 2. Effect of nucleoside analogues against HIV-1 LAI in
CEM-SS cells.
EC50 mM CC50 mM
8-Me2-N-dA 2a .100 .100
8-Et,Me-N-dA 2b .100 .100
8-Et2-N-dA 2c .100 .100
8-(CH2)4-N-dA 2d .100 .100
8-(CH2)5-N-dA 2 e .100 .100
8-iPr-N-dA 2f 14.261.9 81.366.1
8-iBu-N-dA 2g .100 .100
8-MeS-dA 3 .100 .100
8-NH2-CO-dA 7 .100 .100
8-vinyl-dA 8 .100 .100
8-Et-dA 9 .100 .100
The 50% Effective Concentration (EC50) was determined by measuring the RT
activity in cell culture supernatants. The 50% Cytotoxic Concentration (CC50) on
uninfected cells was assessed using an MTT assay. Results are expressed as the
mean value 6 the standard deviation from four independent experiments.
doi:10.1371/journal.pone.0027456.t002
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possible that the phosphorylation steps and/or incorporation of
the triphosphorylated analogues by HIV-1 RT are limiting. To
investigate the latter hypothesis, testing the incorporation of the
triphosphorylated forms of the nucleoside analogues during
reverse transcription is crucial. Unfortunately, synthesis and
purification of the triphosphorylated forms of the 29-dA analogues
proved to be extremely difficult and could not be achieved in
sufficient amount up to now.
On the basis of our in vitro assays, a first structure-activity
relationship can be established. In the case of the C-aminated
derivatives, the absence of any delayed chain termination activity
for 8-iBu-N-dA (2g) compared to 8-iPr-N-dA (2f) indicates that
the presence of an additional methylene group in the amine
introduced at position 8 of the adenine moves the isopropyl group
sufficiently away not to disturb the nucleic acidNRT interactions
that are necessary for efficient polymerisation. By contrast, the
case of 8-Et,Me-N-dA (2b) indicates that the presence of two alkyl
substitutions on the amine, leading to the presence of a tertiary
amine in position 8 of the adenine, inhibits the incorporation of
the next incoming dNTP. However, the same substitution, when
already embedded into a DNA primer, does inhibit DNA synthesis
at a distance from the active site and impairs the incorporation of a
natural dNTP when present in the template strand. Importantly,
for all the other nucleoside analogues tested, the steric hindrance
created by the modifications does not seem to perturb the
interactions that are necessary for the incorporation of the next
incoming dNTP and the size of the modifications still seems
appropriate to interfere with the crucial nucleic acidNRT contact
points. At the same time, these modifications also interfere with
base pairing of the complementary natural dNTP during (+) strand
DNA synthesis. Notably, in the latter case, there is no delayed
effect and the blockage of DNA synthesis is immediate, at the
modification site. Observation of the crystal structure of a P/TNRT
complex [34] reveals that the presence of a modification on
position 8 of the purine ring in the template, at the polymerisation
site, would most likely create a steric clash with Phe61 and Leu74,
within the b3 and b4 sheets of the finger subdomain of HIV-1 RT,
thus explaining the immediate arrest of DNA synthesis. Leu74
anchors the template to RT, making it all the more difficult for
resistance mutations to be acquired at this position, since any
changes would affect the stability of the P/TNRT complex.
In conclusion, we have evidenced a modification site, position 8
of 29-deoxyadenosine, which induces delayed polymerisation
arrest by HIV-1 RT in vitro. In addition, 8-iPr-N-dA is the first
compound to be described that inhibits viral replication through
this particular mechanism and exhibits a relatively low cytotoxic
effect for a first generation compound.
One of the main reasons to believe that DCTs are an interesting
family of new RT inhibitors to be investigated is their likelihood to
escape the resistance pathway that involves excision of the NRTI.
This is indeed possible due to the incorporation of a few natural
nucleotides before polymerization is stalled. After removal of the
last natural nucleotide at the 39 of the primer, removal of the
penultimate nucleotide will compete with re-incorporation of the
last one. As excision is negligible when polymerization is possible,
RT will never manage to remove 3 or 4 successive nucleotides.
Importantly, delayed chain termination reported for the nucleo-
side analogue ETV protects the elongated primer from excision.
Thus, phosphorolytic removal of our DCTs by WT and resistant
HIV-1 RT will require further investigation.
Because, unlike NRTIs approved by the Food and Drug
Administration (FDA), our DCTs have no modification on the
ribose moiety, they should present no cross-resistance with these
drugs. More importantly, because of the delayed chain termination
mechanism, HIV-1 will be unable to select mutations conferring
resistance to DCTs by the existing mechanisms. In addition, as no
side chain of the RT active site is in the vicinity of the modifications
introduced (Figure 1B), there should be no steric hindrance issues
preventing DCT incorporation by HIV-1 RT. Thus, the only way
for RT to become resistant will be to select for amino acids in the
thumb domain that will accommodate the modifications of DCTs.
However, as the primer/template complex moves along the RT, the
DCTs will interact with numerous amino acids of the RT thumb,
and thus multiple mutations would be required to achieve
resistance. In addition, to accommodate the bulky modifications
of DCTs, RT would have to select amino acids with small side-
chains that will be unable to maintain crucial interactions with the
unmodified regions of the primer. Thus, resistance will be difficult to
acquire or will be achieved at the prize of a highly reduced viral
fitness, giving a chance to the host immune system to control the
resistant virus.
Materials and Methods
Nucleoside synthesis
Chemical syntheses were carried out using material and
manipulations described previously [37]. Amines introduced at
position 8 were purchased from Aldrich. They were dried over
KOH and distilled before use. UV, mass spectrometry, 1H
(300 MHz) and 13C (75 MHz) NMR data of all compounds are
available in Dataset S1.
8-Amino-29-deoxyadenosine derivatives (2 a–e). A suspension
of 500 mg (1.51 mmol) of 8-bromo-29-deoxyadenosine[35] (1) in
methanol (25 ml) was reacted 24 h at room temperature with
(30 mmol) of the corresponding amine (a: 15 ml of a
2 M solution of dimethylamine in MeOH; b: 2.6 ml of
ethylmethylamine; c: 3.1 ml of diethylamine; d: 2.5 ml of
pyrrolidine; e: 3.0 ml of piperidine). The reaction mixture was
evaporated to dryness and the residue was purified by column
chromatography (0–10% MeOH in CH2Cl2) to afford the
targeted compounds ((2a: 90% yield (400 mg, 1.36 mmol); 2b:
97% yield (452 mg, 1.46 mmol); 2c: 85% yield (417 mg,
1.29 mmol); 2d: 89% yield (430 mg, 1.34 mmol); 2e: 86%
yield (434 mg, 1.30 mmol)).
8-Amino-29-deoxyadenosine derivatives (2 f–g). A
suspension of 500 mg (1.51 mmol) of 8-bromo-29-deoxyadenosine
(1) in methanol (25 ml) was reacted 24 h at 65uC with (30 mmol)
of the corresponding amine (f: 2.6 ml of isopropylamine; g: 3.0 ml
of isobutylamine). The reaction mixture was evaporated to dryness
and the residue was purified by column chromatography (0–10%
MeOH in CH2Cl2) to afford the targeted compounds ((2f: 60%
yield (280 mg, 0.91 mmol); 2g: 68% yield (330 mg, 1.02 mmol)).
8-Methylthio-29-deoxyadenosine (3). A solution of 2 g
(6.06 mmol) of 8-bromo-29-deoxyadenosine (1) in DMF (2.4 ml)
was treated by a 25% aqueous solution of MeSNa (848.5 mg in
3.4 ml H2O) and stirred at room temperature for 3 h. The
reaction mixture was neutralized by a 1 M solution of HCl.
Solvents were eliminated under reduced pressure and crude
material was dissolved in hot water. Two batches of crystallization
afforded the title compound 3 in 86% yield (1.54 g, 5.19 mmol).
39,59-Di-O-acetyl-8-methylthio-29-deoxyadenosine (4). A
mixture of 1.49 g (5 mmol) of 8-methylthio-29-deoxyadenosine 3
and 1.88 ml (20 mmol) of acetic anhydride in 25 ml of dry
pyridine was stirred at room temperature for 5 h. Water (500 ml)
was added, the mixture was evaporated under reduced pressure
and co-evaporated successively with toluene, methanol and
dichloromethane. Crude material was purified by column
chromatography (5–8% MeOH in CH2Cl2). The title compound
was obtained in 97% yield (1.84 g, 4.8 mmol).
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39,59-Di-O-acetyl-8-methylsulfonyl-29-deo-xyadenosine
(5). A solution of 1.45 g (3.8 mmol) of compound 4 in an acetic
acid/water mixture (50 ml, vol/vol, 50/50) was cooled to 0uC and
treated with 1.61 g (10 mmol) of KMnO4. The mixture was
stirred at 0uC for 45 min and H2O2 was added until solution
decolorized. The resulting mixture was extracted 3 times with
CHCl3, the combined organic layers were dried over Na2SO4 and
concentrated to dryness. The residue was purified by column
chromatography (0–5% MeOH in CH2Cl2) to give compound 5
in 89% yield (1.40 g, 3.37 mmol).
39,59-Di-O-acetyl-8-cyano-29-deoxyadeno-sine (6). A
mixture of 1.00 g (2.4 mmol) of compound 5 and 152 mg
(3.1 mmol) of NaCN in DMF (4.8 ml) was stirred at room
temperature for 3 h and neutralized (pH=7) by addition of a 1 M
solution of HCl. The mixture was diluted with water and the
compound was extracted once with ethyl acetate. The organic
layer was dried over Na2SO4, concentrated to dryness and purified
by column chromatography (0–10% MeOH in EtOAc) to give
compound 6 in 80% yield (790 mg, 2.19 mmol).
8-Carbamoyl-29-deoxyadenosine (7). A suspension of
600 mg (1.69 mmol) of 39,59-di-O-acetyl-8-cyano-29-deoxyadenosine
6 in 35 ml of water was treated with 8.2 ml of a 1 M solution of
NaOH. The reaction mixture was stirred at room temperature for
7 h before the neutralization with a Dowex resin (50Wx8 H+). The
resin was filtrated off, the solvents were eliminated and the residue
was crystallized from water to give pure 8-carbamoyl-29-deoxy-
adenosine with 56% yield (278 mg, 0.94 mmol).
8-Vinyl-29-deoxyadenosine (8). Starting from 8-bromo-29-
deoxyadenosine, this compound was prepared according to the
procedure previously described [35].
8-Ethyl-29-deoxyadenosine (9). Starting from 8-bromo-29-
deoxyadenosine, this compound was prepared according to a
procedure previously described [38].
Phosphoramidites and ODN synthesis
1H (300 MHz) and 13C (75 MHz) NMR data of compounds are
available in Dataset S2.
6-N-Dimethylformamidine-nucleosides (10 a-g, 11 and
12). About 1.0 mmol of the modified nucleoside (2 a–g, 3 or 7)
in methanol (4 ml) was treated with 667 ml (5.0 mmol) of N,N’-
dimethylformamide-dimethylacetal and stirred overnight at room
temperature. The reaction mixture was diluted with ethyl acetate,
the organic layer was washed with saturated aqueous NaHCO3
and brine, dried over Na2SO4 and evaporated. Column
chromatography (0–10% MeOH in CH2Cl2) afforded the N-6
amino protected nucleosides. Starting quantities, yields and mass
analyses are given in Table S1.
59-O-Dimethoxytrityl-6-N-dimethylforma-midine-
nucleosides (13 a–g, 14 and 15). About 0.8 mmol of
nucleoside (10 a–g, 11 or 12) in 8 ml of dry pyridine was
treated at room temperature with 312 mg (0.92 mmol) of
dimethoxytritylchloride. After 17 h the reaction was quenched
with water and the solvents were removed under vacuum. The
residual oil was dissolved in ethyl acetate and washed successively
with saturated aqueous NaHCO3, brine and water. The organic
layer was dried over Na2SO4, evaporated to dryness and co-
evaporated with toluene, methanol and dichloromethane. The
residue was purified by flash silica gel column chromatography (0
– 2% MeOH in CHCl3 with 1% Et3N) to give the targeted
compounds 13 a–g, 14 and 15. Starting quantities, yields and
mass analyses are available in Table S1.
6-N-Dimethylformamidine-59-O-dimethoxy-trityl-8-vinyl-
29-deoxyadenosine (17). The synthesis of compound 17 starting
from compound 16 and its characteristics are described in [35].
59-O-Dimethoxytrityl-8-ethyl-29-deoxyadenosine (18).
150 mg (0.26 mmol) of 8-vinyl-59-O-dimethoxytrityl-29-
deoxyadenosine 16 [35] was introduced in a Schlenk reactor,
dissolved in a mixture of EtOAc and CH2Cl2 and flushed with
Ar. before adding a catalytic amount of Pd/C (10%, 0.05 eq.).
The reaction mixture was successively and 3 times degassed
under vacuum and saturated with H2. After 4 h stirring, the
reaction mixture was successively and 3 times degassed under
vacuum and saturated with Ar. It was then filtered through
Celite and diluted with EtOAc. The organic phase was washed
with 10 ml of water, saturated aqueous NaHCO3 and brine,
dried over Na2SO4 and evaporated to dryness. The ethyl derivative
18was obtained in 94% yield (141 mg, 0.24 mmol) sufficiently pure
to be engaged in the next step without further purification.
6-N-Dimethylformamidine-59-O-dimethoxy-trityl-8-ethyl-
29-deoxyadenosine (19). To a solution of 100 mg (0.17 mmol)
of compound 18 in 570 mL DMF was added 114 mL (0.86 mmol)
of N,N’-dimethylformamide-dimethylacetal. After 4 h stirring at
room temperature under Argon the reaction was diluted with
EtOAc. The organic phase was washed with water, saturated
aqueous NaHCO3 and brine, dried over Na2SO4 and evaporated
to dryness. The amino protected product 19 was obtained
quantitatively (100 mg, 0.17 mmol) sufficiently pure to be
engaged in the next step.
Preparation of the amidite building blocks 20 a–g, 21, 22,
23 and 24. About 0.5 mmol of starting material dried under
reduced pressure for 24 h was dissolved in 7 ml of CH2Cl2
freshly dried over P2O5 and distilled. 340 ml (2.00 mmol) of
N,N-diisopropylethylamine and 164 ml (0.75 mmol) of chloro-
cyanoethyl-N,N’-diisopropyl-phosphora-midite were successively
added to the solution. After 2.5 h stirring at room temperature,
MeOH was added and the reaction was diluted with CH2Cl2. The
organic phase was washed once with water, twice with saturated
aqueous NaHCO3 and brine, dried over Na2SO4 and evaporated
to dryness. The crude yellow oil was purified by chromatography
over silica gel using a mixture of cyclohexane/acetone/NEt3
(50:50:1) as eluent. The phosphoramidite thus obtained was
dissolved in a minimal volume of toluene. The resulting solution
was added dropwise to cold hexane (20 volumes, 220uC) to give
the targeted phosphoramidite as an amorphous solid. Starting
quantities, yields, mass analyses and 31P NMR are available in
Table S2, for compound 23 data are from Ben Gaied et al. [35].
ODN synthesis was performed on an Applied Biosystem ABI 392
DNA synthesizer using the phosphoramidite chemistry at 1 mmol
scale. Solid supports (Universal Support II and Ac-dC-CPG-500)
as well as dT, Ac-dC, Pac-dA and iPr-Pac-dG phosphoramidites
were purchased from Eurogentec. The standard DNA assembly
protocol dimethoxytrityl-off (DMTr-off) was used except for the
following modifications. Dichloroacetic acid (3%) in dichloro-
methane was used for the removal of DMTr protecting group. 5-
Ethylthio-1-H-tetrazole was used as activating agent. A longer
coupling time (600 s) was used with the modified nucleotide
incoming amidites. Phosphite oxidation was done with 2-butanone
peroxide in dichloromethane (1 M). ODN was cleaved from the
Universal Support by treating with a 2 M ammonia solution in dry
methanol for 30 min at room temperature. ODNs were
deprotected by treatment with concentrated aqueous ammonia
at 60uC for 18 h. ODNs were concentrated to dryness and purified
by HPLC on a Dionex DNA-PacTM PA-100 anion exchange
column (96250 mm) at 60uC with the following gradient system
(A=4 M urea 20.2% acetonitrile 220 mM Mes buffer pH 6.5
21 mM NaClO4 and B=4 M urea 20.2% acetonitrile 220 mM
Mes buffer pH 6.5–400 mMNaClO4) from 15 to 70% of solution B
in solution A in 50 min with a 1 ml/min flow rate.
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Fraction purity was checked by electrophoresis on polyacryl-
amide gels (20% acrylamide, 8 M urea). The product-containing
fractions were pooled and desalted by precipitation in 3 volumes of
EtOH with 10% of sodium acetate 3 M. The ODN mass was
assigned by Maldi-TOF spectrometry and the final concentration
was determined by measuring the absorbance at 260 nm. HPLC
retention time and Maldi-TOF mass analysis are available in
Table S3.
Reverse Transcription assays
Templates, primers and RTs. Viral RNA, comprising the
first 311 nucleotides of the HIV-1 genomic RNA (Mal isolate) was
in vitro transcribed and purified as previously described [39]. 18-,
19 and 31-mer DNA oligodeoxynucleotides containing the modified
29-dA analogues respectively at 39 end, at the penultimate position
of 39 end and at a distance of 12 nucleotides from their 59 end were
chemically synthesized and purified as described above (Figure 5).
Unmodified and modified 18- and 19-mer primers were labelled at
their 59 end with [c-32]ATP using phage T4 polynucleotide kinase
and purified on 8% denaturing polyacrylamide gels. RNase H (2)
reverse transcriptase bearing the E478Q mutation that abolishes
RNase H activity (RTEQ) [40] was expressed and purified according
to a method adapted from [41].
Primer/template (P/T) complexes, at a final concentration of
300 nM, were formed by incubating the primer with a 3 fold
excess of either 1–311 viral RNA or modified 31-mer DNA
oligonucleotide in water for 2 min at 90uC, cooling on ice for
2 min and incubating for 20 min at 50uC in 100 mM NaCl.
Minus strong-stop and ‘‘+6’’ DNA synthesis. Ten nM P/
T (with the 311 vRNA as template) were pre-incubated with 10 or
30 nM of RT at 37uC for 4 min. Reactions were initiated by the
addition of 50 mM of each of the four dNTPs and stopped at
various times with equal amounts of buffer containing formamide.
The same procedure was used for synthesis of ‘‘+6’’ DNA except
that ddATP was substituted for dATP. Reaction products were
denatured for 2 min at 90uC prior to separation on an 8%
polyacrylamide denaturing gel and quantified using a Fuji FLA-
5100 analyser and the Image Gauge program.
Plus-strand DNA synthesis. Thirty one-mer DNA
templates, containing or not a modified 29-deoxyadenosine were
hybridized to an 18-mer DNA primer (Figure 5) and subsequent
DNA synthesis and analysis of the reaction products were
performed as described above.
HIV-1 inhibition and toxicity of the nucleoside analogues
in cell culture
The activity of the nucleoside analogues 2a–g, 3, 7, 8 and 9 on
HIV-1 replication was determined by measuring the RT activity
associated with virus particles released from CEM-SS cells infected
with HIV-1 Lai. The 50% cytotoxic concentration (CC50) was
evaluated in parallel to the 50% inhibitory concentration (IC50)[37].
Supporting Information
Figure S1 1D and 2D Noesy spectra of 8-iBu-N-dA and 8-
iPr-N-dA. Experiments were performed in DMSO-d6 as solvent.
1D 1H NMR were recorded on a 300 MHz apparatus and 2D
Noesy on a 500 MHZ apparatus.
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Figure S2 Comparative effect of 8-MeS-dA on (2) and
(+) strand DNA synthesis. A. Templates and primers used
for the study. The template is either 1–311 HIV-1 MAL RNA,
for which part of the sequence is shown, or a 41-mer DNA
oligonucleotide. The primer is a 19- mer DNA strictly
complementary to the central part of the template. X
corresponds to either dAMP or 8-MeS-dAMP inserted at the
penultimate position of the primer. ‘‘n’’ corresponds to the
position of the modified nucleotide. B. Time course of in vitro
DNA synthesis using 10 nM of primer/template complexes
preincubated with either 10 or 90 nM of HIV-1 RT.
Polymerization was initiated by the addition of 20 mM of
dTTP, dGTP and dCTP as well as 50 mM of ddATP for the
RNA-directed synthesis or 20 mM of dATP, dTTP, dCTP and
50 mM of ddGTP for the DNA directed synthesis. Reactions
were stopped after 15, 60 and 120 min. (+6) and (+7) refer to
the 6th and 7th nucleotides to be added with respect to the
position of the modified nucleotide analogue.
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building blocks.
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24. Starting quantities, yields, mass analyses and 31P NMR.
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Table S3 Retention time on anion exchange HPLC
column and Maldi-TOF mass of oligodeoxynucleotides.
HPLC was performed on a Dionex DNA-PacTM 28 PA-100 anion
exchange column (96250 mm) at 60uC with the following gradient
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